Compare Gilead Sciences, Inc. (GILD) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs SkyWest Inc — how do they compare? Gilead Sciences, Inc. trades at $132.94 (market cap $163.51B), while SkyWest Inc trades at $100.41 (market cap $3.95B). The key difference: Gilead Sciences, Inc. is far larger — about 41.4× SkyWest Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while SkyWest Inc pays none. Which is the better fit depends on your goals.
| GILD | SKYW | |
|---|---|---|
Market Cap | $163.51B | $3.95B |
Sector | Health | Technology |
52-Week High | $155.80 | $123.72 |
52-Week Low | $108.22 | $78.40 |
Enterprise Value | $178.05B | $5.79B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
SkyWest (SKYW) trades at $100.50, up 3.41% with strong technical momentum and bullish analyst sentiment. The stock shows solid fundamentals with a P/E of 9.54, net margin of 10.42%, and recent earnings beats. Recent management changes and consistent profitability support the positive outlook despite fuel cost pressures affecting the airline industry.
The stock presents upside potential with a consensus price target of $109.33 (8.8% upside) and no sell ratings. Key risks include volatile fuel costs and industry margin pressures, but strong cash flow generation and attractive valuation provide a compelling risk-reward profile for investors seeking exposure to regional airlines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
